Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

Completed · Phase 2

Conditions studied: Head and Neck Cancer

In brief

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent and/or metastatic head and neck cancer.

Key facts

Study ID

NCT00281866

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

37

Starts

2005-07-01

Expected to finish

2007-03-01

Last updated by the study team

2016-10-12

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• Hospital Universitario 12 de Octubre — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.